Aimmune's peanut allergy treatment could 'change practice' — with safety challenges and a price anything but peanuts

Aimmune Therapeutics $AIMT has detailed the results of its Phase III study of its peanut allergy therapy known as AR101 in the New England Journal of Medicine in an article — and independent assessment — that will likely stoke its supporters as much as the skeptics in the field.